AARD (Aardvark Therapeutics) Beginning Cash Position: $47.05 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AARD Aardvark Therapeutics Inc AARD
12 GF Score
Price $5.99
! 1 Warning Sign
View Full Analysis

What is Aardvark Therapeutics Beginning Cash Position?

Aardvark Therapeutics AARD -5.00% 12 Beginning Cash Position is $47.05 Mil as of Mar. 2026. GuruFocus rates AARD with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Aardvark Therapeutics's Beginning Cash Position for the quarter that ended in Mar. 2026 was $47.05 Mil.

Aardvark Therapeutics's quarterly Beginning Cash Position increased from Sep. 2025 ($26.00 Mil) to Dec. 2025 ($39.29 Mil) and increased from Dec. 2025 ($39.29 Mil) to Mar. 2026 ($47.05 Mil).

Aardvark Therapeutics's annual Beginning Cash Position declined from Dec. 2023 ($15.56 Mil) to Dec. 2024 ($9.74 Mil) but then increased from Dec. 2024 ($9.74 Mil) to Dec. 2025 ($61.64 Mil).

Aardvark Therapeutics Beginning Cash Position Related Terms

Aardvark Therapeutics Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Aardvark Therapeutics's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aardvark Therapeutics Beginning Cash Position Chart

Aardvark Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
26.88 15.56 9.74 61.64

Aardvark Therapeutics Quarterly Data
Dec22 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 61.64 26.50 26.00 39.29 47.05
AARD
12GF Score
Aardvark Therapeutics Inc AARD
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aardvark Therapeutics Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $47.05 Mil mean?
Aardvark Therapeutics (AARD) has a Beginning Cash Position of $47.05 Mil as of Mar. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Aardvark Therapeutics and its competitors.
Is Aardvark Therapeutics' Beginning Cash Position too high?
Aardvark Therapeutics' current Beginning Cash Position is $47.05 Mil. Overall, Aardvark Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Aardvark Therapeutics' Beginning Cash Position compare to KLRS and VANI?
Aardvark Therapeutics' Beginning Cash Position of $47.05 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Aardvark Therapeutics and its competitors. Aardvark Therapeutics's current Beginning Cash Position is $47.05 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aardvark Therapeutics stock overvalued right now?
Aardvark Therapeutics (AARD) has a current Beginning Cash Position of $47.05 Mil. The current Beginning Cash Position is $47.05 Mil. Aardvark Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Aardvark Therapeutics (AARD), the current Beginning Cash Position is $47.05 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aardvark Therapeutics Business Description

Address 4370 La Jolla Village Drive, Suite 1050, San Diego, CA, USA, 92122
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
12GF Score

Get the complete analysis for AARD

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.99
Price